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Available online 3 June 2017Cross-talk between hematopoietic stem cells (HSCs) and bone marrow stromal cells (BMSCs) is essential for
HSCs regulation and leukemogenesis. Studying bone marrow of myelodysplasia patients, a pre-leukemic condi-
tion, we found mRNA overexpression of vascular endothelial growth factor A (VEGFA) in CD34+ HSCs and
semaphorin 3A (SEMA3A) in BMSCs. To better understand the role of VEGFA and SEMA3A in leukemogenesis,
we recruited 30myelodysplastic syndrome (MDS) patients, 29 acutemyeloid leukemia (6 secondary toMDS) pa-
tients and 12 controls.We found higherVEGFA expression in de novoAML patients (without priorMDS) group (p
= 0.0073) and higher SEMA3A expression in all BMSCs patient's samples compared to control group. We then
overexpressed VEGFA in an acute myelogenous leukemia cell line, KG1 cells, and in normal CD34+ cells. This
overexpression increased KG1 (p = 0.045) and CD34+ cell (p = 0.042) viability and KG1 (p = 0.042) and
CD34+ cell (p = 0.047) proliferation. Moreover, KG1 and CD34+ cells overexpressing VEGFA also had increased
proliferation when co-cultured with human marrow stromal HS5 cells (p = 0.045 and p = 0.02, respectively).
However, co-culture of these transformed cells with HS5 cells overexpressing SEMA3A reduced KG1 (p =
0.004) and CD34+ (p=0.009) proliferation. Co-culture of KG1 transformed cells with HS27 cells overexpressing
SEMA3A reduced KG1 proliferation as well (p= 0.01). To investigate whether the dominant SEMA3A effect over
VEGFA could be due to competition for neuropilin1 receptor (NRP1), we performed immunoprecipitation with
anti-NRP1 antibody of cell extracts of co-cultured KG1 and HS5 cells, induced or not by VEGFA and SEMA3A re-
combinant proteins. Results showed a preferential association of NRP1 with SEMA3A, suggesting that SEMA3A
can partially reverse the effects caused by the VEGFA preventing its binding with the NRP1 receptor. Since
both hematopoietic cells, leukemic and normal, showed similar behavior, we suppose that the attempt to rever-
sion of VEGF effects by SEMA3A is a homeostatic phenomenon in the hematopoietic niche. Finally, we conclude
that VEGFA overexpression confers AML cell advantages and SEMA3A may partially reverse this effect; thus,
SEMA3A protein combined with VEGFA inhibitors could be beneficial for AML treatment.MRC, Ac
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Hematopoietic stem cells (HSCs) are capable of self-renewal and of
differentiating into mature blood cells (Jagannathan-Bogdan & Zon,
2013) and the cross talk between HSCs and Bone marrow stromal
cells (BMSCs), in the bone marrow microenvironment, is essential forute myeloid leukemia
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an open access article underHSCs regulation (Morrison & Scadden, 2014). This homeostasis may
be interrupted by mutations in the HSC, caused by errors induced by
aging, environment, hereditary factors among other factors (Wilson et
al., 2008). The most frequent hematological disease of aging are the
myelodysplastic syndromes (MDS), in which acquired mutations in
HSC lead to deregulation of signaling pathways, conferring risk of clonal
expansion and progression to acutemyeloid leukemia (AML) (Albitar et
al., 2002). Nowadays, the differentiation between both MDS and AML is
mainly based on the number of immature, supposedly neoplastic, cells
in the bone marrow, being 20% the cutoff number (MDS - b20% and
AML - 20% or more) Patients with MDS have low or high risk to evolve
to AML, depending on genetic, epigenetic and/or immunological factors
(Vardiman et al., 2009).
Recent studies have shown that the cross-talk between leukemic
stem cells, which are a small fraction of leukemic cells capable of self-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics of the participants in the study.
CD34+ cells BMSCs
Normal controls 8 5
Gender (male/female) 3/5 4/1
Age (years), median (range) 40 (29–49) 40 (28–54)
MDS patients 18 25
Gender (male/female) 12/6 18/7
Age (years), median (range) 69 (27–77) 70 (16–90)
Low-risk (RCUD/RCMD/RARS) 11 (0/9/2) 18 (0/16/2)
High-risk (RAEB-1/RAEB-2) 07 (1/6) 07 (2/5)
AML patients 15 17
Gender (male/female) 4/11 7/10
Age (years), median (range) 63 (34–87) 63 (30–86)
Secondary/de novo 4/11 5/12
BMSCs, bonemarrow stromal cell; MDS,myelodysplastic syndrome; RARS, refractory ane-
miawith ringed sideroblasts; RAEB, refractory anemia with excess of blasts; RCUD, refrac-
tory cytopenia with unilineage dysplasia; RCMD, refractory cytopenia with multilineage
dysplasia.
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Similarly, myelodysplastic cells require a type of cancer stem cell for
myelodysplastic syndrome (MDS) development (Woll et al., 2014).
For a better knowledge of the interaction between leukemic and stro-
mal cells, our group performed a microarray study using bone marrow
cells from MDS patients and found VEGFA overexpression in progenitor
CD34+ cells and SEMA3A overexpression in BMSCs (Baratti et al., 2010).
SEMA3A is a secreted protein characterized by its role in migration
and guidance of axons in the developing nervous system. SEMA3A can
only bind to neuropilin 1 receptor (NRP1), however neuropilins are un-
likely to transduce SEMA3A signals on their own due to their short in-
tracellular domain, thereby, complex formation with Plexin A
receptors is necessary for signal transduction (Neufeld et al., 2012).
NRP1 serve as co-receptors for VEGFA; VEGFA is a proangiogenic fac-
tor widely known and, due to alternative splicing, the VEGFA gene gen-
erates multiple isoforms among which VEGF165 is the most abundant.
VEGFR1 and VEGFR2 are the main receptors for VEGF165, however the
complex formation with NRP1 co-receptor can enhance their signaling
(Neufeld et al., 1999). Studies have described increased VEGFA mRNA
(Fiedler et al., 1997), plasma levels (Aguayo et al., 2002) and protein ex-
pression (Verstovsek et al., 2002) in AML patients and correlationwith a
worse prognosis (Gerber & Ferrara, 2003), however the role of VEGFA in
MDS remains controversial (Aguayo et al., 2002; Verstovsek et al., 2002;
Bellamy et al., 2001; Wimazal et al., 2006; Gianelli et al., 2013).
An antagonistic role of VEGFA and SEMA3A has been implicated in
several solid tumors (Chekhonin et al., 2013; Bender & Mac Gabhann,
2015); while VEGFA increases tumor growth and metastasis
(Chekhonin et al., 2013), SEMA3A is associated to lower migration and
invasion rates (Pellet-Many et al., 2008), and to a better prognosis
(Janssen et al., 2012). Moreover, there is a disagreement as to whether
VEGF165 and SEMA3A opposite effects could be due to NRP1 binding
competition (Pellet-Many et al., 2008). The aim of this study is to better
understand the interaction of VEGFA and SEMA3A in the bone marrow
of MDS and AML patients.
2. Materials and Methods
2.1. Patients and controls
The study included patients with a confirmed diagnosis of MDS or
AML, untreated at the time of sample collection. BoneMarrow (BM) as-
pirates from healthy donors, MDS, and AML patients were collected ac-
cording to institutional guidelines. Assignment to different MDS (high
and low risk) and AML (secondary to MDS or Myelodysplasia-Related
Changes (MRC) and de novo) groups was decided according to the
2008 World Health Organization classification (Vardiman et al., 2009);
acute promyelocytic leukemia patients were excluded. For gene expres-
sion analysis, CD34+ or BMSCs were isolated from BM aspirates of 12
healthy donors, 30 MDS (22 low risk and 08 high risk) and 29 AML
(06 secondary to MDS/MRC and 23 de novo) untreated patients who
attended the outpatient clinic at the Hematology and Transfusion Cen-
ter of the University of Campinas (Hemocentro-UNICAMP) from 2006
to 2016 (Table 1). Some patients were donors for both CD34+ cells
and BMSCs. For VEGFA overexpression assay, normal CD34+ cells were
isolated from umbilical cord blood after deliveries and samples were
processed within 24 h of collection. This study was approved by the
Ethics Committee of the University of Campinas and healthy donors
and patients provided informed written consent.
2.2. CD34+ cell and BMSCs selection
BMor cord bloodmononuclear cellswere isolated by Ficoll-Hypaque
Plus density-gradient centrifugation (GE Healthcare) and labeled with
CD34 MicroBeads (Miltenyi Biotec). CD34+ cells were isolated by
MIDI-MACS immunoaffinity columns (Miltenyi Biotec) and purity was
determined by flow cytometry (minimum 90%), using anti-CD34antibody. The remainingmononuclear cellswere plated ontoDulbecco's
modified Eagle's medium (DMEM; Sigma) supplemented with 10% FBS.
Supernatant containing nonadherent cells was removedweekly and re-
placed with fresh supplemented medium. When the monolayer was
established (90% confluence), cells were trypsinized and plated under
the same conditions. After three replatings, a homogeneous cell popula-
tion was obtained and BMSCswere evaluated by flow cytometry for the
absence of CD31, CD34, CD45, CD68, andHLA-DR antigens and presence
of CD73, CD90, and CD105.
2.3. Cell Lines and Recombinant Proteins
KG1 cell line, which was obtained from a 59-year-old Caucasian
malewith erythroleukemia that evolved into acutemyelogenous leuke-
mia and expresses the CD34 antigen (Morimoto et al., 1994), and the
HS5 and HS27 cell lines, two different clones of a long term bone mar-
row cell obtained from a 30-year-old Caucasian male that were trans-
formed with the amphotropic retrovirus vector LXSN16E6E7
(Roecklein & Torok-Storb, 1995), were obtained from ATCC, Philadel-
phia, PA. Cells were cultured in RPMI-1640 medium containing 10%
FBS, 2 mM glutamine, 100 mg/mL penicillin, 100 mg/mL streptomycin,
0.25 mg/mL amphotericin B and maintained in a humidified atmo-
sphere at 37 °C, 5% CO2. For immunoprecipitation assay, co-culture of
KG1 and HS5 cells were treated with 100 ng/mL of VEGF 165
(PeproTech) and 250 ng/mL of SEMA3A Fc Chimera (R&D Systems)
human recombinant proteins.
2.4. Quantitative polymerase chain reaction
All sampleswere assayedwith cDNA (Revert AidHMinus First Strand
cDNA Synthesis Kit; MBI Fermentas), SYBR Green Master Mix PCR (MBI
Fermentas) and specific primers in the MasterCycler ep Realplex
(Eppendorf). Relative gene expressionwas calculated using the equation
2−ΔΔCt (Livak & Schmittgen, 2001). Control was performed for each
primer pair. Amplification specificity was verified using a dissociation
curve at the end of each run. Three replicas were run on the same plate
for each sample. The following primers were used: VEGFA, 5′-
ATCGAGACCCTGGTGG ACAT-3′ and 5′-GTGCTGGCCTTGGTGAGG-3′;
SEMA3A, 5′-TGTATGTTGGAGCAAAGGAT-3′ and 5′-TCTGGTGTAAG
ATACTGGCC -3′ (Baratti et al., 2010) and HPRT, 5′GAACGTCTTG
CTCGAGATGTGA-3′ and 5′-TCCAGCAGGTCAGCAAAGAAT-3′.
2.5. Vector construction and lentivirus transfection
For cell line overexpression, 0.57 kb full-length human VEGF 165
(OriGene) or 2.3 kb full-length human SEMA3A cDNA (OriGene) were
amplified by RT-PCR and cloned into pENTR vector (Invitrogen)
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action was completed between pENTR-VEGFA 165 or pENTRSEMA3A
vectors and pLenti6/V5-Dest vector (Invitrogen) to generate pLenti-
VEGF 165 or pLenti-SEMA3A, engineered to express VEGF 165 and
SEMA3A respectively. pLenti-LacZ (Invitrogen) was used as control.
Lentivirus packaging and titteringwere performedby Capital Bioscience
Inc. (Gaithersburg, MD). KG1 cells were transducedwith lentivirus-me-
diated pLenti-VEGF 165or pLenti-LacZ andnamedVEGFA and Lacz cells,
respectively. Briefly, 2 × 105 cells were transduced with lentivirus by
spinoculation at multiplicity of infection equal to 5 and selected by 1
μg/mL blasticidin S. HS5 cells were transducedwith lentivirus-mediated
pLenti-SEMA3A or pLenti-LacZ and named SEMA3A and Lacz cells, re-
spectively. Briefly, HS5 cells were seeded into six-well plates at 2
× 105 cells/well, grown overnight, and transduced with lentiviral vec-
tors at multiplicity of infection equal to 5 and selected by 1 μg/mL
blasticidin S. Gene and protein expression of VEGFA and SEMA3A
were confirmed by RT-PCR and immunoblotting. Functional assays
were performed after 48 h of incubation.2.6. Vector construction and Nucleofection®
For CD34+ overexpression, a 0.57 kb full-length human VEGF
165 (OriGene) were amplified by RT-PCR and cloned into pMig
vector. The empty vector pMig was used as control. For
Nucleofection®, 5 × 104 CD34+ cells were suspended in 20 μl of
Nucleofection® buffer solution for human primary cells (P3 Prima-
ry Cell 4DNucleofector™ X Kit, Lonza) containing pMig-VEGFA or
pMig plasmid DNA using the EO-100 program of the Amaxa 4D-
Nucleofector. Immediately after Nucleofection®, cells were trans-
ferred into 500 μl of pre-warmed DMEM medium supplemented
with 20% FBS, 50 ng/mL SCF and 10 ng/mL IL-3. Gene expression
was confirmed by RTPCR.2.7. Co-culture of HS5 or HS27 and KG1 or CD34+ cells
Stromal feeder layers from HS5 or HS27 cells in the nontransduced,
Lacz/SEMA3A transduced conditions were seeded in 6-well culture
plates (2 × 105 cells/well for co-culture with KG-1 cells) or 24-well cul-
ture plates (2 × 104 cells/well for co-culture with CD34+ cells) in RPMI-
1640medium containing 10% FBS and incubated for 12 h at 37 °C. After
this period, nonadherent cells were seeded onto stromal cell mono-
layers (1 × 106 KG1 or 1 × 105 CD34+ cells/well) and incubated for
72 h at 37 °C. Nonadherent cells were removed and functional assays
were performed.2.8. Cell viability assay
KG1 cell viability was determined by MTT assay as previously de-
scribed (Mosmann, 1983). Briefly, 2.5 × 104 cells/well was seeded in
100 μl RPMI-1640 10% FBS medium. Next, 10 μl of a 5 mg/mL solution
of MTT were added to the cells followed by incubation at 37 °C for 4 h.
The reaction was stopped using 100 μl of 0.1 N HCl in anhydrous
isopropanol. Cell viability was evaluated by measuring the absorbance
at 570 nm, using an automated plate reader. Conditions were tested in
six replicates.
CD34+ cell viability was determined by Cell-titer 96 aqueous solu-
tion cell proliferation assay kit (Promega) according to the
manufacturer's instructions. Briefly, 1 × 104 cells/well were seeded in
DMEM 20% FBS, 50 ng/mL SCF and 10 ng/mL IL-3 supplemented medi-
um. Next, 20 μl of cell-titer 96 aqueous solution were added to the
cells followed by incubation at 37 °C for 2 h. Absorbance was read at
490 nm, using an automated plate reader. Conditions were tested in
two replicates.2.9. Cell proliferation assay (Ki-67 staining)
5 × 105 cells were fixed with 70% ethanol and stored at−20 °C. Ki-
67 stainingwas performed according to themanufacturer's instructions
(BD Bioscience). Mean of fluorescence intensity (M.F·I) was obtained
by flow cytometry using a FACS Calibur (Becton Dickinson). Blank
cells (without KI-67 staining) were used as negative control for each
condition. Acquired data were analyzed using FlowJo software.
2.10. Colony formation assay
Colony formation was carried out in semisolid methylcellulose me-
dium (2 × 103 cell/mL; MethoCult 4230 for KG1 cells or 4435 for
CD34+ cells; StemCell Technologies Inc.). KG1 colonies were detected
after 7 days of culture by adding 1 mg/mL of MTT reagent and scored
by Image J quantification software (U.S. National Institutes of Health).
CD34+ colonies were characterized and scored according to their mor-
phology with an inverted microscope at 40× magnification in a culture
dish marked with a scoring grid. The colonies were classified into CFU-
GM (Colony-forming unitgranulocyte/macrophage) and BFU-E (Burst-
forming unit-erythroid). Conditions were replicated twice.
2.11. Detection of apoptosis by Annexin V and PI staining
1.25 × 105 cells were fixed with 70% ethanol and stored at−20 °C.
Cells were washed twice with PBS and resuspended in binding buffer
containing 1 μg/mL PI and 1 μg/mL APC labeled Annexin-V (BD Biosci-
ence). All specimens were analyzed by flow cytometry (FACS Calibur)
after incubation for 15 min at room temperature in a light protected
area. Acquired data were analyzed using FlowJo software. Conditions
were replicated twice.
2.12. Immunoprecipitation and Western blot
Equal amounts of protein were used for total extracts or for immu-
noprecipitation with specific antibodies, followed by SDS-PAGE and
Western blot analysis with the indicated antibodies (carried out using
the ECL™Western Blotting Analysis System; AmershamPharmacia Bio-
tech Ltd., Buckinghamshire, UK). Antibodies against Plexin-A4 (Santa
Cruz, CA), VEGF Receptor 2 (Cell Signaling Technology, MA), Neuropilin
(NRP-1) (Santa Cruz, CA). For VEGFA and SEMA3A protein expression,
the antibodies used were Anti-VEGF 165A (ABCAM, Cambridge, AM),
anti-SEMA3A (Santa Cruz, CA) and normalized by anti-Actin (Santa
Cruz, CA).
2.13. Statistical analysis
Statistical analyses were performed using GraphPad Instat 5
(GraphPad Software, Inc., San Diego, CA, USA) and SAS System for Win-
dows (Statistical Analysis System, 9.4. SAS Institute Inc., 2002–2012,
Cary, NC, USA.). For patient's comparisons, Mann–Whitney test was
used. For functional assay comparisons, Student t-test and Anova test
were used, as appropriate. A P value b 0.05was considered as statistical-
ly significant.
3. Results
3.1. Increased expression of VEGFA and SEMA3A in patient bone marrow
cells
The first step of our study comprised evaluation ofmRNA expression
of VEGFA in CD34+ cells and SEMA3A in BMSCs from MDS, AML and
healthy donor BM aspirates. VEGFAmRNA expression was significantly
increased in CD34+ cells from de novo AML patients compared with
healthy donors (5.06 [0.42–57.52] vs 1.00 [0.8–2.19], P = 0.0073)
(Fig. 1 A). SEMA3A mRNA expression was significantly increased in
Fig. 1. VEGFA expression is increased in CD34+ cells of de novo AML patients and SEMA3A is increased in BMSCs of MDS and AML patients compared to control cells. VEGFA and SEMA3A
mRNA expression in healthy donors andMDS andAML patients. RTPCRwas performedon cDNA fromBMCD34+ or BMSCs. Each dot indicates the relative VEGFA or SEMA3A expression for
each patient. Horizontal lines represent medians. mRNA expression levels were normalized by HPRT endogenous control. (A) VEGFAmRNA expression was significantly higher in CD34+
cells from de novoAMLpatients comparedwith healthy donors (P=0.0073). (B) SEMA3AmRNA expressionwas significantly higher in BMSCs fromMDS low-Risk (P=0.027),MDSHigh-
Risk (P = 0.005), secondary AML (P = 0.05) and de novo AML (P = 0.007) patients compared with healthy donors;Mann-Whitney test.
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BMSCs from healthy donors: MDS low-risk (2.97 [0.64–24.39] vs 0.83
[0.43–2.86], P = 0.028), MDS high-risk (9.50 [2.34–22.60] vs 0.83
[0.43–2.86], P = 0.005), Secondary AML (3.07 [0.97–6.97] vs 0.83
[0.43–2.86], P = 0.05) and de novo AML (5.73 [1.10–28.21] vs 0.83
[0.43–2.86], P = 0.007) (Fig. 1 B).
3.2. VEGFA overexpression increased proliferation of KG1 and CD34+ cells
We further evaluated the role of VEGFA overexpression. We chose
the leukemic cell line KG1 because it expressed a low level of VEGF
and then could be used for VEGF overexpression (Supplementarydata). However, normal CD34+ cells exhibited an even lower level of
VEGFmRNA (Supplementary data). The KG1 cell line was stably trans-
duced with lentivirus-mediated targeting VEGFA or Lacz (Control).
After antibiotic selection, the efficiency of VEGFA overexpression was
verified by qPCR and Western blotting (Supplementary data). CD34+
cells were nucleofected® with Mig-VEGFA or Mig vectors and the effi-
ciency of VEGFA overexpression was verified by qPCR (Supplementary
data). We next evaluated the effects of VEGFA overexpression on cell vi-
ability, proliferation, colony formation and apoptosis.
VEGFA ovexpression significantly increased the viability of KG1
(124.4 ± 23.03% vs 100 ± 0.62%; P = 0.003) (Fig. 2 A1) and CD34+
cells compared to control (159.6 ± 41.2% vs 102.5 ± 16.93%; P =
Fig. 3. SEMA3A effects are dominant over VEGFA in co-culture assays using KG1 and
stromal cell lines (HS5 and HS27). KG1 proliferation was determined by KI-67 M.F.I.
flow cytometry after co-culture of: (A) KG1 VEGFA or KG1 Lacz and HS5 non-
transduced cells, (B) HS5 SEMA3A or HS5 Lacz and KG1 non-transduced cells, (C) KG1
VEGFA or KG1 Lacz and HS5 SEMA3A or HS5 Lacz. (D) KG1 VEGFA or KG1 Lacz and
HS27 SEMA3A or HS27 Lacz. Results are shown as mean ± SD, the numbers of
independent experiments are indicated; Student t-test, and Anova test. (E) Colonies
containing viable KG1 cells were detected by MTT in cells co-cultured for 72 h with HS5
cells, followed by 07 days in culture with methylcellulose. Results are shown as mean
± SD, the number of independent experiments are indicated; Anova test.
Fig. 2. VEGFA overexpression increased cell proliferation. (A1) KG1 viability was
determined by MTT assay after 48 h of incubation. (A2) CD34+ viability was determined
by Cell-titer 96 aqueous solution cell proliferation assay kit after 96 h of incubation.
Results are shown as mean ± SD, the numbers of independent experiments are
indicated; Anova test. (B1) KG1 and (B2) CD34+ cell proliferation was determined by Ki-
67 M.F.I. after incubation for 48 h. Results are shown as mean ± SD, the numbers of
independent experiments are indicated; Student t-test.
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increased proliferation of KG1 (107.7 ± 2.82%; P = 0.042) (Fig. 2 B1)
and CD34+ cells (134.0 ± 7.68%; P = 0.047) (Fig. 2 B2). Regarding col-
ony formation and apoptosis, VEGFA ovexpression had no effect in KG1
or CD34+cells (data not shown).
3.3. SEMA3A effects are dominant over VEGFA in co-culture assays
To determine whether VEGFA and SEMA3A had opposite effects in
leukemia cells, we performed co-culture assays using HS5 or HS27 stro-
mal and KG1 leukemic cell lines. It is important to point out that stromal
cell line HS5 as well as normal BMSCs extracted from cord blood
showed low levels of SEMA3A mRNA (Supplementary data). HS5 and
HS27 cell lines were stably transduced with lentivirus-mediated
targeting SEMA3A or Lacz (Control). After antibiotic selection, the
efficiency of SEMA3A overexpression was verified by qPCR andWestern
blotting (Supplementary data). KG1 and HS5 cells were co-cultured for
72 h under three conditions: KG1 VEGFA or KG1 Lacz and HS5 non-
transduced cells; HS5 SEMA3A or HS5 Lacz and KG1 nontransduced
cells; and KG1 VEGFA or KG1 Lacz and HS5 SEMA3A and HS5 Lacz
cells. KG1 andHS27 cellswere co-cultured for 72 h under one condition:
KG1 VEGFA or KG1 Lacz and HS27 SEMA3A and HS27 Lacz cells. KG1
non-adherent cells were then harvested, and proliferation, apoptosis
and colony formation assays were performed.
In HS5 and KG1 co-cultures, Ki-67 analysis revealed an increased
proliferation of KG1 cells overexpressing VEGFA when co-cultured
with HS5 cells (176.9 ± 46.34%; P = 0.045) (Fig. 3A). However, co-cul-
ture with HS5 SEMA3A cells decreased the proliferation of KG1 cells
compared with HS5 Lacz co-culture (93.15 ± 0.79%; P = 0.004)
(Fig. 3B). Finally, SEMA3A effects were dominant over VEGFA effects
as co-culture of KG1 VEGFA and HS5 SEMA3A showed reduced prolifer-
ation compared to KG1 Lacz plus HS5 Lacz (67.15 ± 22.09%; P b 0.001)or KG1 VEGFA plus HS5 Lacz coculture (118.8 ± 13.67% vs 91.97 ±
5.26%; P b 0.001) (Fig. 3C). In HS27 and KG1 cocultures, Ki-67 analysis
also revealed that SEMA3A effects were dominant over VEGFA effects
as co-culture of KG1 VEGFA and HS27 SEMA3A showed reduced prolif-
eration compared to KG1 VEGFA plus HS27 Lacz (137.3 ± 10.83% vs
159.4 ± 15.12%; P = 0.016) or KG1 Lacz plus HS27 SEMA3A co-culture
(137.3 ± 10.83% vs 149.6 ± 16.34%; P = 0.016) (Fig. 3D).
Co-culture with HS5 SEMA3A cells did not alter colony formation of
KG1 cells. However, co-culture of KG1 VEGFA and HS5 Lacz cells in-
creased the number of KG1 colonies compared to KG1 Lacz and HS5
Lacz co-culture (163.9 ± 37.81%; P = 0.004). The number of KG1 colo-
nies decreased in KG1 VEGFA andHS5 Lacz co-culture compared to KG1
Lacz and HS5 SEMA3A (163.9 ± 37.81% vs 101.0 ± 31.27%; P= 0.008);
and in the co-culture of KG1 VEGFA andHS5 Lacz cells compared to KG1
VEGFA and HS5 SEMA3A cells (163.9 ± 37.81% vs 106.9 ± 35.42%; P =
0.011) (Fig. 3E).
Fig. 4. SEMA3A effects are dominant over VEGFA in co-culture assays using CD34+ cells from cord blood and HS5 cell line. CD34+ proliferation was determined by KI-67 M.F.I. flow
cytometry after co-culture of: (A) CD34+ MIG VEGFA or CD34+ MIG and HS5 nontransduced cells, (B) HS5 SEMA3A or HS5 Lacz and CD34+ non-transduced cells, (C) CD34+ MIG
VEGFA or CD34+ MIG and HS5 SEMA3A or HS5 Lacz. Results are shown as mean ± SD, the numbers of independent experiments are indicated, Student t-test and Anova test.
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the coculture conditions (data not shown). Thus, these results indicated
that in the absence of SEMA3A, VEGFA overexpression increased prolif-
eration of KG1 cells co-culturedwith HS5 cells. However, in the absence
of VEGFA, SEMA3A overexpression decreased proliferation of KG1 cells.Fig. 5. Preferential association of NRP1 receptor with SEMA3A over VEGFA. Immunoprecipitat
NRP1 antibody were performed using total extracts from KG1 and HS5 cocultured cells und
(treated with recombinant VEGFA protein (100 ng/μL)), SEMA3A cells (treated with rec
recombinant VEGFA protein (100 ng/μL) and with recombinant SEMA3A protein (250 ng/μL)
cell extracts (TCE) were also analyzed.When we combined KG1 VEGFA e HS5 SEMA3A cells, the SEMA3A ef-
fects were dominant over VEGFA.
To determine whether VEGFA and SEMA3A had opposite effects in
CD34+ normal cells, we performed co-culture assays using HS5 stromal
cell line and CD34+ cells from umbilical cord blood. CD34+ and HS5ion (IP) assay with NRP1 antibody and immunoblotting (IB) with Plexin-A4, VEGFR2 and
er four conditions: Control cells (Without recombinant protein treatment), VEGFA cells
ombinant SEMA3A protein (250 ng/μL)) and VEGFA + SEMA3A cells (Treated with
). Isotype IgG antibody was used as a negative control of the immunoprecipitation; total
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VEGFA or CD34+ MIG and HS5 non-transduced cells; HS5 SEMA3A or
HS5 Lacz and CD34+ non-transduced cells; and CD34+ MIG VEGFA or
CD34+ MIG and HS5 SEMA3A or HS5 Lacz cells. CD34+ non-adherent
cells were then harvested and proliferation, apoptosis and colony for-
mation assays were performed.
Ki-67 analysis revealed an increased proliferation of CD34+ cells
overexpressing VEGFAwhen co-cultured with HS5 cells (131.8 ± 7.9%;
P = 0.02) (Fig. 4A). However, co-culture with HS5 SEMA3A cells de-
creased the proliferation of CD34+ cells compared with HS5 Lacz co-
culture (55.05 ± 23.29%; P = 0.03) (Fig. 4B). Finally, SEMA3A effects
were dominant over VEGFA effects since the co-culture of CD34+ MIG
VEGFA and HS5 SEMA3A showed reduced proliferation compared to
CD34+ MIG plus HS5 Lacz (52.24 ± 23.77%; P b 0.001) or CD34+ MIG
VEGFA plus HS5 Lacz co-culture (107.7 ± 2.76% vs 52.54 ± 23.77%; P
b 0.001) (Fig. 4C).
VEGFA or SEMA3A ovexpression did not alter CD34+ colony forma-
tion or apoptosis in any of the co-culture conditions (data not shown).
These results indicated that in the absence of SEMA3A, VEGFA overex-
pression increased proliferation of CD34+ cells co-cultured with HS5
cells. However, in the absence of VEGFA, SEMA3A overexpression de-
creased proliferation of CD34+ cells. When we combined VEGFA and
SEMA3A overexpression, the SEMA3A effects were dominant over
VEGFA.
3.4. Preferential association of NRP1 receptor with SEMA3A over VEGFA
To investigate whether the dominant SEMA3A effect over VEGFA
could be due to competition for the NRP1 receptor, we performed im-
munoprecipitation assay using antibody anti-NRP1 receptor followed
by immunoblotting of anti-VEGFR-2 (VEGFA receptor) and anti-
Plexin-A4 (SEMA3A coreceptor). The protein was collected from KG1
and HS5 cells after co-culture and treated under these conditions: Con-
trol (No recombinant protein), VEGFA Recombinant (100 ng/μL),
SEMA3A Recombinant (250 ng/μL) and both recombinant proteins. Im-
munoblotting revealed that, in the combined presence of VEGFA and
SEMA3A recombinant proteins, there was a greater association of
NRP1 with Plexin-A4 (SEMA3A coreceptor) than with VEGFR-2
(VEGFA receptor), probably favoring SEMA3A signaling (Fig. 5). These
results suggest that the dominant effect of SEMA3A could be over pref-
erential association with NRP1 receptor.
4. Discussion
The importance of bonemarrowmicroenvironment in leukemogen-
esis becomes more evident each day. Kim and colleagues described the
ability of leukemic stem cells to reset the communication between he-
matopoietic stem cells and the bonemarrowmicroenvironment, induc-
ing leukemogenesis (Kim et al., 2015). With the aim of better
understanding this interaction, we investigated the relationship be-
tween VEGFA and SEMA3A in AML and MDS bone marrows. We found
a significant increase of VEGFA in CD34+ cells of de novo AML bonemar-
rows. Moreover, SEMA3A was significantly increased in BMSC of AML
and MDS samples, compared to healthy controls. VEGFA increase has
been described in several types of cancer and correlates with worse
prognosis in solid tumors (Ferrara, 2004).
The increase of VEGFmRNA, plasma levels and protein expression in
hematopoietic diseases has been reported and may be correlated with
increased angiogenesis and microvascular density (MVD) in bone mar-
rows of AML patients (Pruneri et al., 1999; Aguayo et al., 2000; Hussong
et al., 2000; de Bont et al., 2001; Song et al., 2015). Increased VEGFA
plasma levels (Aguayo et al., 2002; Aguayo et al., 2000; Lee et al.,
2007; Brunner et al., 2002) and mRNA in mononuclear cells from AML
bone marrows has also been described (Fiedler et al., 1997; Hussong
et al., 2000; de Bont et al., 2001; Mourah et al., 2009); however, to our
knowledge, no data has been reported regarding VEGFA in CD34+cells. In our study, we found no difference between VEGFAmRNA ex-
pression in CD34+ cells from MDS patients and healthy donors. The
disclosed data regarding VEGFA and MDS patients is controversial.
Some authors described a gradual increase of VEGFA plasma levels
and MVD according to MDS progression (Pruneri et al., 1999; Aguayo
et al., 2000), however these results have not yet been confirmed
(Zorat et al., 2001; Madry et al., 2007).
To investigate how VEGF increase influences leukemic cells, we
overexpressed VEGFA in KG1 leukemic cell line, which is CD34+ positive
(Morimoto et al., 1994), and in CD34+ cells isolated from umbilical cord
blood and performed proliferation, viability, apoptosis and colony for-
mation assays.VEGFA overexpression increasedKG1 andCD34+ cells vi-
ability and proliferation. Our data are in accordance with the results of
List and colleagues that described increased proliferation of KG1 cells
after treatment with VEGF recombinant protein (List et al., 2004).
They also reported an unexplained increase in apoptosis rates of KG1
cells treated with VEGFA. However, our study did not find differences
in the apoptosis rates of KG1 VEGFA and KG1 Lacz cells, confirming
that the increased viability herein describedmay be related to increased
proliferation. Further corroborating our data, Xu and colleagues de-
scribed increased viability in leukemic cell line HL-60 after VEGFA over-
expression, despite having also reported decreased apoptosis and
increased colony formation (Xu et al., 2003). Thus, we suggest that in-
creased VEGFA expression confers advantages for leukemic cells that
become more capable of proliferating over normal hematopoietic cells.
Increased VEGFA expression was found only in CD34+ cells from de
novoAML patients; this result is in agreementwith the “paracrine-auto-
crine loop” theory suggested by some authors (Dias et al., 2000; Casella
et al., 2003; Kampen et al., 2013). Leukemic cells are believed to produce
and secrete VEGFA and in a paracrine manner, stimulate BMSCs from
bone marrow microenvironment to produce more VEGFA, other cyto-
kines, andgrowth factors, therefore benefiting leukemic cells in an auto-
crinemanner (Dias et al., 2000; Casella et al., 2003; Kampen et al., 2013).
Our group investigated VEGFA gene expression in BMSCs from low and
high riskMDS, secondary and de novoAML bonemarrows and found in-
creased VEGFA expression in BMSCs from de novo AML patients com-
pared to the control group (unpublished observations) corroborating
the “paracrine-autocrine loop” theory.
Herein, we observed increased SEMA3A gene expression in BMSCs of
all patients compared to the control group. In the literature, we found
two studies of SEMA3A in AML: The first reported that epigenetic chang-
es increases SEMA3A expression and contributes to EZH2 silencing in
patients with secondary AML (Yang et al., 2015). The second described
lower expression of SEMA3A in nonadherent cells from bone marrow
stroma of AML patients compared to the control group (Wang et al.,
2005). Thus, not much is known of the role of SEMA3A in the bonemar-
rowmicroenvironment and more studies are needed to affirm SEMA3A
involvement in the pathogenesis of MDS and AML.
In order to investigate VEGFA and SEMA3A effects in leukemic cells,
we proceeded to co-culture of HS5 stroma cells overexpressing SEMA3A
and KG1 leukemic cells or CD34+ cells overexpressing VEGFA. The
VEGFA overexpression increased proliferation and clonogenicity of
KG1 cells and increased CD34+ cell proliferation; however, had no influ-
ence in apoptosis. On the other hand, co-culture of KG1 or CD34+ cells
with HS5 overexpressing SEMA3A decreased KG1 proliferation and
clonogenicity and decreased CD34+ cell proliferation. These data are
consistent with the anti-angiogenic effects of SEMA3A described in
solid tumors (Tamagnone, 2012; Vacca et al., 2006). When we com-
bined KG1 cells overexpressing VEGFA and HS5 cells overexpressing
SEMA3A, the effect of SEMA3A was dominant over VEGFA, causing de-
creased proliferation and colony formation (Tamagnone, 2012; Vacca
et al., 2006). In co-culture of KG1 cells overexpressing VEGFA and
HS27 cells overexpressing SEMA3A, the effect of SEMA3Awas also dom-
inant over VEGFA, causing decreasedKG1 proliferation. In co-culture as-
says using normal CD34+ cells, the SEMA3A effect was also dominant
and caused decreased CD34+ cell proliferation.
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colony formation of CD34+ cells isolated from umbilical cord blood.
However, increased clonogenicity of bone marrow mononuclear cells
from high-risk MDS patients, after treatment with recombinant VEGF,
has been previously described (Bellamy et al., 2001). These discrepant
results may be related to different signaling pathways activated in nor-
mal and leukemic cells. List and colleagues reported increased colony
formation of KG1 cells dependent on the PI3K/Akt pathway and inde-
pendent of ERK (List et al., 2004). Diversely, Koistinen et al. described in-
creased clonogenicity of the leukemic line OCI/AML-2-dependent on
nitric oxide (Koistinen et al., 2001). Leukemic cells have frequentmuta-
tions that may contribute to dysregulation of signaling pathways (van
Gisbergen et al., 2015), and are not present in CD34+ normal cells,
therefore, we hypothesized that leukemic cells are more committed
and increased VEGFA may be enough to stimulate clonal growth. On
the other hand, normal CD34+ cellsmay bemore effective in controlling
mechanisms of clonogenicity induced by VEGFA overexpression.
Thus, our results suggest that the model proposed for solid tumors,
wherein SEMA3A inhibits the effects caused by VEGFA (Chekhonin et
al., 2013; Bender & Mac Gabhann, 2015) also applies to AML. The over-
expression of VEGFA confers advantages to leukemic cells, by increasing
their proliferation capacity, and SEMA3A inhibits these effects,
preventing the uncontrolled proliferation of leukemic cells. The mecha-
nism mediating this interaction has not yet been elucidated, however
there is speculation that this could be through the competition between
VEGFA and SEMA3A for NRP1 receptor binding (Pellet-Many et al.,
2008). To investigate this hypothesis, we co-cultivated KG1 and HS5
cells treated or not with VEGFA and SEMA3A recombinant proteins
and obtained protein extracts. We then immunoprecipitated anti-
NRP1 receptor and performed immunoblotting with anti-VEGFR2 and
anti-Plexin A4 receptor antibodies. Our results indicated that in the
presence of the two recombinant proteins, the NRP1 receptor preferen-
tially forms complexes with Plexin A4 rather than VEGFR2. The forma-
tion of NRP1 SEMA3Aplexin A4-complex is essential for SEMA3A
signaling (Goshima et al., 2012). These data suggest that the dominant
effect of SEMA3A may be related to the competition for NRP1 binding.
Herein, we describe increased VEGFA and SEMA3A expression in
bone marrow cells from de novo AML patients and the possible domi-
nant effect of SEMA3A, suggesting that SEMA3A could control the ef-
fects caused by VEGFA. However, some questions remain: Why is
SEMA3A expression increased in BMSCs from MDS and secondary AML
patients? If SEMA3A inhibits the effects caused by VEGFA, why do pa-
tients still exhibit uncontrolled proliferation of leukemic blasts?
Little is known regarding the effect of SEMA3A in bone marrowmi-
croenvironment. Due to their tissue-specific effect, SEMA3A could delay
effects caused by other growth factors or could act upon the pathogen-
esis of myeloid diseases. Considering only VEGFA and SEMA3A interac-
tion in de novo AML patient bone marrow, our data suggest that
SEMA3A may have a therapeutic role through inhibition of the effects
caused by VEGFA. Under physiological conditions, VEGF165 and
SEMA3A have been suggested to be involved in a negative feedback.
In endothelial cells, increased VEGF165 expression induces increased
SEMA3A expression as a part of an angiogenic balance; and this feedback
is dysregulated in malignant processes (Vacca et al., 2006; Catalano et
al., 2004). Despite these results, we are aware that SEMA3A protein
alone is not capable of reversing the clinical condition of patients, as
many factors contribute to AML pathogenesis, acting in synergy with
VEGFA (Kornblau et al., 2010). VEGFA has been a target of cancer treat-
ment, including AML and many inhibitors of pathways triggered by
VEGFA have been produced and are under test in clinical protocols
(Garcia-Manero et al., 2015; Gupta et al., 2013). The use of SEMA3A
may add new possibilities to improve this treatment. However, al-
though our study provides insights regarding the clinical relevance of
SEMA3A and VEGFA inMDS and AML, taking into consideration the het-
erogeneity of these diseases, any application as a possible treatment
would no doubt require additional studies in large and unselectedAML patient cohorts, necessary to clarify whether there are exceptional
subsets of patients where this effect is weaker or cannot be seen.
5. Conclusion
Our results suggest thatVEGFA overexpression confers advantages to
leukemic cells, by increasing their proliferation, and SEMA3A protein
may partially reverse the effects caused by VEGFA. Thus, the combined
administration of VEGFA inhibitors and SEMA3A proteinmay be benefi-
cial for treatment of AML patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2017.05.012.
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